Rigel Pharmaceuticals (NASDAQ: RIGL)
Key Data Points
Rigel Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Rigel Pharmaceuticals Company Info
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
News & Analysis
Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?
More data is needed.
3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Why Rigel Pharmaceuticals Stock Jumped Today
The company announced positive results from an important COVID-19 clinical study.
3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring
Here's why this stock's big run-up in recent months could be just the beginning.
Why Rigel Pharmaceuticals Stock Is Jumping Today
The company is teaming up with Eli Lilly on the development of a promising immune disease drug.
Why Rigel Pharmaceuticals Stock Skyrocketed 91% Today
The biotechnology company is hoping to improve coronavirus care.
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
Success in clinical trials doesn't guarantee success on the market.
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.